title: Pharmacological, cell, and gene therapy strategies to promote spinal cord regeneration.
abstract: In this review, recent studies using pharmacological treatment, cell transplantation, and gene therapy to promote regeneration of the injured spinal cord in animal models will be summarized. Pharmacological and cell transplantation treatments generally revealed some degree of effect on the regeneration of the injured ascending and descending tracts, but further improvements to achieve a more significant functional recovery are necessary. The use of gene therapy to promote repair of the injured nervous system is a relatively new concept. It is based on the development of methods for delivering therapeutic genes to neurons, glia cells, or nonneural cells. Direct in vivo gene transfer or gene transfer in combination with (neuro)transplantation (ex vivo gene transfer) appeared powerful strategies to promote neuronal survival and axonal regrowth following traumatic injury to the central nervous system. Recent advances in understanding the cellular and molecular mechanisms that govern neuronal survival and neurite outgrowth have enabled the design of experiments aimed at viral vector-mediated transfer of genes encoding neurotrophic factors, growth-associated proteins, cell adhesion molecules, and antiapoptotic genes. Central to the success of these approaches was the development of efficient, nontoxic vectors for gene delivery and the acquirement of the appropriate (genetically modified) cells for neurotransplantation. Direct gene transfer in the nervous system was first achieved with herpes viral and El-deleted adenoviral vectors. Both vector systems are problematic in that these vectors elicit immunogenic and cytotoxic responses. Adeno-associated viral vectors and lentiviral vectors constitute improved gene delivery systems and are beginning to be applied in neuroregeneration research of the spinal cord. Ex vivo approaches were initially based on the implantation of genetically modified fibroblasts. More recently, transduced Schwann cells, genetically modified pieces of peripheral nerve, and olfactory ensheathing glia have been used as implants into the injured spinal cord.
authors.affiliation: Graduate School Neurosciences Amsterdam, Netherlands Institute for Brain Research.
authors.forename: Bas
authors.initials: B
authors.lastname: Blits
authors.forename: Gerard J
authors.initials: GJ
authors.lastname: Boer
authors.forename: Joost
authors.initials: J
authors.lastname: Verhaagen
mesh_terms: D000818:Animals; D017690:Cell Transplantation; D002921:Cicatrix / Q000517:prevention & control; D018691:Excitatory Amino Acid Antagonists / Q000627:therapeutic use; D016332:Fetal Tissue Transplantation; D015316:Genetic Therapy / Q000379:methods; D006801:Humans; D009416:Nerve Regeneration; D016501:Neurites / Q000648:ultrastructure; D009474:Neurons / Q000637:transplantation; D018696:Neuroprotective Agents / Q000627:therapeutic use; D013119:Spinal Cord Injuries / Q000188:drug therapy / Q000628:therapy*
chemical_list: D018691:Excitatory Amino Acid Antagonists; D018696:Neuroprotective Agents